Page 200 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPTEr 11 Lymphocyte Adhesion and Trafficking 181

The most recent clinically approved selective modulator of 4. Zhang SL, Bhandoola A. Trafficking to the thymus. Curr Top Microbiol
35
an adhesion molecule is vedolizumab. It is a humanized mAb Immunol 2014;373:87–111.
that binds to a combinatorial epitope in α 4 /β 7 integrin but does 5. Chang JE, Turley SJ. Stromal infrastructure of the lymph node and
not interact with α 4 /β 1 and α E / β 7 integrins. This makes vedoli- coordination of immunity. Trends Immunol 2015;36:30–9.
zumab a remarkably selective inhibitor of lymphocyte homing 6. Fu H, Ward EJ, Marelli-Berg FM. Mechanisms of T cell organotropism.
Cell Mol Life Sci 2016;73(16):3009–33.
to the intestine. It has been approved for the treatment of both 7. Germain RN, Robey EA, Cahalan MD. A decade of imaging cellular
ulcerative colitis and Crohn disease. An mAb, etrolizumab, which motility and interaction dynamics in the immune system. Science
targets the β 7 integrin (thus blocking both α 4 /β 7 and α E /β 7 , but 2012;336:1676–81.
not α 4 /β 1 ), which may induce remission in ulcerative colitis, and 8. Sigmundsdottir H, Butcher EC. Environmental cues, dendritic cells and
an anti-MAdCAM-1 antibody that appears to be effective in the programming of tissue-selective lymphocyte trafficking. Nat Immunol
ulcerative colitis, but not in Crohn disease, are in early-phase 2008;9:981–7.
clinical trials. 38 9. Fan X, Rudensky AY. Hallmarks of tissue-resident lymphocytes. Cell
The most feared adverse effect of natalizumab and efalizumab 2016;164:1198–211.
treatment is the possible reactivation of polyoma John Cun- 10. Arnon TI, Cyster JG. Blood, sphingosine-1-phosphate and lymphocyte
ningham (JC) virus, which leads to the development of potentially migration dynamics in the spleen. Curr Top Microbiol Immunol
2014;378:107–28.
39
fatal progressive multifocal leukoencephalopathy (PML). Up 11. Nourshargh S, Alon R. Leukocyte migration into inflamed tissues.
to 1% of natalizumab-treated patients develop PML in the Immunity 2014;41:694–707.
high-risk groups, and more than 700 cases of PML have been 12. Qi H, Kastenmüller W, Germain RN. Spatiotemporal basis of innate and
recorded among natalizumab-treated patients. However, the adaptive immunity in secondary lymphoid tissue. Annu Rev Cell Dev
benefits of this therapy in MS still outweigh the risks. With good Biol 2014;30:141–67.
risk stratification and vigilance, the drug has maintained its status 13. Headland SE, Norling LV. The resolution of inflammation: principles and
as a very effective biological treatment option for MS. Efalizumab, challenges. Semin Immunol 2015;27:149–60.
in contrast, was voluntarily withdrawn from the market in 2009 14. Buckley CD, Barone F, Nayar S, et al. Stromal cells in chronic
upon emergence of PML in the treated patients. Theoretically, inflammation and tertiary lymphoid organ formation. Annu Rev
Immunol 2015;33:715–45.
α 4 /β 7 blocking should not interfere with lymphocyte surveillance 15. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms
functions in the CNS, and in line with this, no PML cases have and clinical consequences. Nat Rev Immunol 2004;4:211–22.
been reported among vedolizumab-treated patients. Mild adverse 16. Vestweber D. How leukocytes cross the vascular endothelium. Nat Rev
effects with SAM therapy include an expected increase in sus- Immunol 2015;15:692–704.
ceptibility to infections and injection site reactions. However, 17. McEver RP. Selectins: initiators of leucocyte adhesion and signalling at
apart from the risk of PML with natalizumab, both natalizumab the vascular wall. Cardiovasc Res 2015;107:331–9.
and vedolizumab seem to have a good overall safety profile. 18. Proudfoot AE, Uguccioni M. Modulation of chemokine responses:
Lymphocyte migration can also be targeted therapeutically synergy and cooperativity. Front Immunol 2016;7:183.
40
by modulating lymphocyte exit from the lymph nodes. 19. Sallusto F, Baggiolini M. Chemokines and leukocyte traffic. Nat Immunol
Fingolimod/FTY720 causes S1P receptor internalization and 2008;9:949–52.
degradation. Consequently, it is a functional antagonist of SIP 20. Kinashi T. Overview of integrin signaling in the immune system. Methods
Mol Biol 2012;757:261–78.
receptors 1, 3, 4, and 5. It inhibits lymphocyte egress from the 21. Jordan AR, Racine RR, Hennig MJ, et al. The role of CD44 in disease
lymphoid organs. It may selectively retain CCR7-positive T cells, pathophysiology and targeted treatment. Front Immunol 2015;6:182.
including central memory T cells, which may be particularly 22. Salmi M, Jalkanen S. Cell-surface enzymes in control of leukocyte
important for the pathogenesis of brain inflammation, while trafficking. Nat Rev Immunol 2005;5:760–71.
sparing CCR7-negative effector memory cells. It has been 23. Salmi M, Jalkanen S. Ectoenzymes in leukocyte migration and their
approved by the US Food and Drug Administration (FDA) as therapeutic potential. Semin Immunopathol 2014;36:163–76.
the first-line treatment for relapsing MS, and it is the first orally 24. Braun A, Worbs T, Moschovakis GL, et al. Afferent lymph-derived T cells
active disease-modifying drug for this immunological disease. and DCs use different chemokine receptor CCR7-dependent routes for
More selective S1P receptor 1 antagonists, such as ozanimod, entry into the lymph node and intranodal migration. Nat Immunol
2011;12:879–87.
have shown preliminary efficacy in IBD. Although used in certain 25. Cyster JG, Dang EV, Reboldi A, et al. 25-Hydroxycholesterols in innate
clinical indications, targeting of chemokine/chemokine receptors and adaptive immunity. Nat Rev Immunol 2014;14:731–43.
for manipulating lymphocyte migration has not yet proceeded 26. Debes GF, Arnold CN, Young AJ, et al. Chemokine receptor CCR7
to clinical applications. required for T lymphocyte exit from peripheral tissues. Nat Immunol
2005;6:889–94.
Please check your eBook at https://expertconsult.inkling.com/ 27. Salmi M, Karikoski M, Elima K, et al. CD44 binds to macrophage
for self-assessment questions. See inside cover for registration mannose receptor on lymphatic endothelium and supports lymphocyte
details. migration via afferent lymphatics. Circ Res 2013;112:1577–82.
28. Karikoski M, Marttila-Ichihara F, Elima K, et al. Clever-1/stabilin-1
controls cancer growth and metastasis. Clin Cancer Res 2014;20:6452–64.
REFERENCES 29. Gonzalez-Cabrera PJ, Brown S, Studer SM, et al. S1P signaling: new
therapies and opportunities. F1000Prime Rep 2014;6:109.
1. Gowans JL, Knight EJ. The route of recirculation of lymphocytes in the 30. Notarangelo LD, Badolato R. Leukocyte trafficking in primary
rat. Proc R Soc Lond B Biol Sci 1964;159:257–82. immunodeficiencies. J Leukoc Biol 2009;85:335–43.
2. Girard JP, Moussion C, Förster R. HEVs, lymphatics and homeostatic 31. DeLisser HM, Christofidou-Solomidou M, Sun J, et al. Loss of endothelial
immune cell trafficking in lymph nodes. Nat Rev Immunol surface expression of E-selectin in a patient with recurrent infections.
2012;12:762–73. Blood 1999;94:884–94.
3. Mazo IB, Massberg S, von Andrian UH. Hematopoietic stem and 32. Etzioni A. Defects in the leukocyte adhesion cascade. Clin Rev Allergy
progenitor cell trafficking. Trends Immunol 2011;32:493–503. Immunol 2010;38:54–60.